Allogene Therapeutics wants to bring its experimental lymphoma drug to more patients by arguing that CAR-T cell therapy is worth the manufacturing hassle. The problem: two drugs already on the market are making that argument harder.
CAR-T — chimeric antigen receptor T-cell therapy — requires extracting a patient's blood, engineering their T cells to recognize cancer, and infusing them back weeks later. For patients with aggressive lymphoma, that wait can be life-threatening. Epcoritamab and glofitamab are bispecific antibodies — a class of drug that bridges a patient's immune cells to tumor cells, redirecting the immune system to attack cancer without that delay. Both won FDA approval in 2023 for relapsed or refractory diffuse large B-cell lymphoma, the same blood cancer that CAR-T therapies target. Both are accumulating real-world outcomes data every month while CAR-T is still scaling up.
This is the architectural competition Allogene is walking into. The company reported interim data this week showing its experimental CAR-T, called cema-cel, cleared residual cancer cells in 58.3 percent of lymphoma patients treated, compared with 16.7 percent of patients who were simply observed after initial chemotherapy, according to BioSpace. The trial also reported zero cases of cytokine release syndrome or ICANS — the severe immune reactions that complicate treatment with existing CAR-T products like Kymriah and Yescarta. None of the 12 patients who received cema-cel experienced either event.
The results sent Allogene's stock up more than 50 percent in pre-market trading on April 13. The company also announced a $175 million public offering the same day — a 50 percent stock pop makes dilution less painful. But the trial's primary endpoint, event-free survival, is not expected until mid-2027. The stock moved on a surrogate.
What Allogene is trying to prove is whether cema-cel can move CAR-T earlier in the treatment sequence. The ALPHA3 trial is testing it as a first-line consolidation treatment for patients who have completed initial chemotherapy but remain at high risk of relapse — earlier than where bispecifics are approved, which is after at least two prior therapies have failed. The idea is to prevent relapse before it happens rather than treat it after. Allogene CEO David Chang has said his company's mission is democratizing cell therapy, expanding access and simplifying delivery for physicians and treatment centers, per BioSpace. Whether that democratization happens depends on what the 2027 readout shows.
The bispecifics are not waiting. Epcoritamab is administered by subcutaneous injection. Glofitamab is given as an intravenous infusion on a fixed schedule. A cost-of-care analysis published in Leukemia & Lymphoma found glofitamab produced per-patient savings compared with epcoritamab across all treatment cycles studied. The drugs are competing on economics as well as efficacy.
The CAR-T field has treated bispecifics as a competing technology to be distinguished by superior durability of response, per the Nature Blood Cancer Journal. The theory is that a cell therapy engineered once and administered once provides longer-lasting benefit than a drug that must be dosed repeatedly. That theory has not yet been tested in a head-to-head trial against the current generation of bispecifics. Until it is, the practical choice for relapsed patients will continue to favor whatever is fastest and most reliably available.
For now, the MRD clearance data is real and the safety profile is clean. Whether it translates into the kind of durable benefit that justifies CAR-T's manufacturing complexity and cost is what the Phase 3 readout will determine. The democratization of lymphoma treatment is already underway through bispecifics available today. Whether Allogene is leading that shift or arriving late is what the 2027 readout will determine.
